Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | C119 - Rapidly Progressive Dementia

Wednesday 04/06/22
07:00 AM - 09:00 AM PDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Michael D. Geschwind, MD, PhD, FAAN
Aging, Dementia, Cognitive, and Behavioral Neurology
This course is designed to help clinicians when presented with a patient with a rapidly progressive dementia (RPD) or related syndrome, to understand the evaluation pathway and how it differs from that of a typical or slowly progressive dementia syndrome; develop and apply a diagnostic algorithm for various testing, including ruling out potentially reversible or curable etiologies; and provide practical framework for diagnosis of autoimmune encephalitis.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student
Case-based, Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
07:00 AM - 07:05 AM PDT Introduction Outline of Course
Michael D. Geschwind, MD, PhD, FAAN
07:00 AM - 07:00 AM PDT Speaker Walk-in Slides
Michael D. Geschwind, MD, PhD, FAAN
07:05 AM - 08:00 AM PDT Speaker Prion and other non-autoimmune mediated RPDs
Michael D. Geschwind, MD, PhD, FAAN
08:00 AM - 08:05 AM PDT Break Stretch, Tea, Coffee
08:05 AM - 08:45 AM PDT Speaker Autoimmune and Antibody-mediated Causes of RPD
Jeffrey Marc Gelfand, MD, MAS, FAAN
08:45 AM - 09:00 AM PDT Q&A Questions and Answers
Jeffrey Marc Gelfand, MD, MAS, FAAN, Michael D. Geschwind, MD, PhD, FAAN
Faculty Disclosures
Michael D. Geschwind, MD, PhD, FAAN Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Jeffrey Marc Gelfand, MD, MAS, FAAN Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant and Expert, Vaccine Injury Compensation Program with United States Health and Human Services and Department of Justice. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.